How do I buy Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock?

Buying Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "RCKT", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy RCKT by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if RCKT is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) Stock

Q: What is the minimum investment for RCKT on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Rocket Pharmaceuticals, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · RCKT

Trade RCKT

Key stats

Market cap: $272.24M
Price / Earnings ratio: -15.6x
EPS (TTM): -$0.16
Volume: Loading
52-week high: $5.45
52-week low: $2.17

Source: third-party data provider, as of November 13, 2026

Compare with RCKT

Technical indicators

RSI 14: 48.10
MACD 12/26/9: -0.05
EMA 9 of MACD: -0.09
MACD histogram: 0.04
SMA 50: $2.77; Price below SMA 50
EMA 50: $2.70; Price below EMA 50
SMA 200: $3.40; Price below SMA 200
EMA 200: $3.23; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 5 analyst ratings

Strong Sell0

Sell0

Hold2

Buy3

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

680M449M224M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-223.1M

Net income

Earnings

No data available

Source: third-party data provider

About Rocket Pharmaceuticals, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees202

CEODr. Gaurav D. Shah M.D.

IPO DateFeb 6, 2015

HeadquartersCranbury, NJ

Key Executives

Name	Title	Year Born
Dr. Gaurav D. Shah M.D.	CEO & Director	1975
Mr. Christopher Stevens	Chief Operating Officer	1980
Mr. Martin Louis Wilson J.D.	Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer	1976
Mr. Joseph Manhede	Principal Accounting Officer	1978
Dr. Jonathan Schwartz M.D.	Chief Science & Gene Therapy Officer	1964
Ms. Meg E. Dodge J.D., L.L.M.	Senior Vice President & Head of External Affairs	—
Dr. Syed Ali-Aamir Rizvi M.D.	Chief Medical Officer	1967
Kevin Giordano	Director of Corporate Communications	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-5.7	-7.7
2022	-29.7	+0.2	-4.9	-37.2	+10.9	+22.9	+0.3	+12.2	+1.2	+20.4	-0.6	+6.4
2023	+13.4	-12.6	-15.4	+0.2	+14.3	-5.1	-9.6	-12.4	+28.1	-6.9	+22.8	+28.0
2024	-2.6	+0.4	-11.8	-19.5	-5.4	-1.8	+17.1	-15.2	+2.6	-2.7	-15.3	-12.8
2025	-15.6	-10.5	-24.1	+31.3	-68.1	-11.6	+17.8	+9.7	+0.6	+19.3	-3.9	+11.1
2026	+0.6	+44.0	-28.0	-3.9	-13.8	+13.2	-11.6	+9.1	-29.5	-5.8	+0.4

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Rocket Pharmaceuticals, Inc. Common Stock (RCKT) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "RCKT", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy RCKT by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Rocket Pharmaceuticals, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Rocket Pharmaceuticals, Inc. Common Stock (RCKT) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track RCKT's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) Stock

Key stats

Compare with RCKT

Recent news

Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference

Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference

Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

RCKT Aligns With FDA on Completing Phase II Study in Danon Disease

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

About Rocket Pharmaceuticals, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade